SEC 13F Intelligence

Meritech Capital Associates V L.L.C. / TXG

Meritech Capital Associates V L.L.C.’s 10x Genomics Inc Position

Does Meritech Capital Associates V L.L.C. own 10x Genomics Inc (TXG)? Not currently — the last reported position was 494.2K shares worth $10M in Q2 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$10M
Q2 2024
Shares
494.2K
% of Portfolio
+3.30%
Quarters Held
15
position exited

Position History TXG

Reported value by quarter
Q4 ’20: $365MQ4 ’20Q1 ’21: $384MQ2 ’21: $351MQ2 ’21Q3 ’21: $261MQ4 ’21: $240MQ4 ’21Q1 ’22: $102MQ2 ’22: $48MQ2 ’22Q3 ’22: $30MQ4 ’22: $39MQ4 ’22Q1 ’23: $42MQ2 ’23: $42MQ2 ’23Q3 ’23: $20MQ4 ’23: $28MQ4 ’23Q1 ’24: $19MQ2 ’24: $10MQ2 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q2 2024494.2K$10M+3.30%
Q1 2024494.2K$19M+6.20%
Q4 2023494.2K$28M+6.73%
Q3 2023494.2K$20M+6.49%
Q2 2023750.5K$42M+10.04%
Q1 2023750.5K$42M+8.80%
Q4 20221.06M$39M+9.44%
Q3 20221.06M$30M+5.16%
Q2 20221.06M$48M+7.43%
Q1 20221.34M$102M+9.59%
Q4 20211.61M$240M+7.68%
Q3 20211.79M$261M+7.80%
Q2 20211.79M$351M+7.51%
Q1 20212.12M$384M+9.49%
Q4 20202.58M$365M+30.70%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Meritech Capital Associates V L.L.C.’s full portfolio or all institutional holders of TXG.